Journal of Neural Transmission

, Volume 111, Issue 8, pp 1053–1063

Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson’s Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study

  • M. Onofrj
  • A. Thomas
  • F. Vingerhoets
  • W. Martin
  • S. Giménez-Roldán
  • J.-P. Azulay
  • G. Bernhard
  • W. Schmidt
  • S. Markabi
Article

DOI: 10.1007/s00702-004-0149-4

Cite this article as:
Onofrj, M., Thomas, A., Vingerhoets, F. et al. J Neural Transm (2004) 111: 1053. doi:10.1007/s00702-004-0149-4
  • 114 Downloads

Summary.

The efficacy of entacapone and its impact on patient quality of life (QOL) was investigated in an open-label study of 899 patients with idiopathic Parkinson’s Disease (PD) experiencing wearing-off fluctuations. Patients were divided into 3 groups (3, 4 or 5 doses daily) based on their current levodopa dosage frequency. Patients received 200 mg entacapone with each levodopa/dopa-decarboxylase inhibitor (DDCI) dose, while continuing their same levodopa/DDCI dosage regimen for 4 weeks. Primary efficacy measure was the Investigators’ Clinical Global Impression of Change (CGIC). Patient QoL was assessed using the validated 8-item Parkinson’s Disease Questionnaire (PDQ-8). Investigators’ CGIC revealed that 76.5% of entacapone treated patients experienced an improvement in global status after 4 weeks. Treatment with entacapone was also associated with improvement in patient QoL, with a mean reduction (improvement) in PDQ-8 score of 1.8 from baseline. This study confirms and extends the results of earlier studies demonstrating that, independent of dosing frequency, completing levodopa/DDCI therapy with entacapone provides clinically relevant improvements in global status and QoL in PD patients experiencing wearing-off on their current levodopa dosing frequency.

Keywords: Entacapone, levodopa, Parkinson’s disease, wearing-off 

Copyright information

© Springer-Verlag/Wien 2004

Authors and Affiliations

  • M. Onofrj
    • 1
  • A. Thomas
    • 1
  • F. Vingerhoets
    • 2
  • W. Martin
    • 3
  • S. Giménez-Roldán
    • 4
  • J.-P. Azulay
    • 5
  • G. Bernhard
    • 6
  • W. Schmidt
    • 6
  • S. Markabi
    • 6
  1. 1.Servizio di NeurofisiopatologiaPescaraItaly
  2. 2.Responsible de l’Unité des Maladies Neurodégénératives, Service de NeurologieLausanneSwitzerland
  3. 3.University of Alberta, Glenrose Rehabilitation HospitalEdmontonCanada
  4. 4.Hospital General Universitario Gregorio MaranónMadridSpain
  5. 5.Department of NeurologyUniversity Hospital La TimoneMarseilleFrance
  6. 6.Novartis Pharma AGBaselSwitzerland

Personalised recommendations